SPRO

Spero Therapeutics, Inc. [SPRO] Stock Forecast

Q: What is Spero Therapeutics, Inc. stock symbol ?

Spero Therapeutics, Inc. is a US stock, located in Cambridge of Massachusetts and trading under the symbol SPRO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

Stock Summary

Earnings have grown 95.67% per last year.

Profit margins (-12.91%) are lower than the previous year (-4.92%)

Top 10 Correlated ETFs

SPRO

Top 10 Correlated Stocks

SPRO

In the News

06:32 03 Oct 2022 SPRO

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?

02:30 03 Oct 2022 SPRO

Hot Penny Stocks To Watch As The Stock Market Crash Continues

Hot penny stocks to add to your watch list this week. Is it time to buy?

12:47 03 Oct 2022 SPRO

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

06:00 03 Oct 2022 SPRO

Reddit Penny Stocks to Watch as September Ends

Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10:53 03 Oct 2022 SPRO

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.

09:56 03 Oct 2022 SPRO

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics.

06:00 03 Oct 2022 SPRO

Looking for Popular Penny Stocks to Buy? 3 to Watch Now

Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?

12:02 03 Oct 2022 SPRO

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

10:34 03 Oct 2022 SPRO

Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?

Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).

08:05 03 Oct 2022 SPRO

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022. Details for the presentation are as follows:

Financial details

Company Rating

Neutral

Market Cap

70.14M

Income

-113.27M

Revenue

8.77M

Book val./share

1.09

Cash/share

1.38

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 Nov 2022

P/E

-0.58

Forward P/E

PEG

6.81

P/S

7.52

P/B

1.84

P/C

1.45

P/FCF

-0.79

Quick Ratio

3.3

Current Ratio

3.65

Debt / Equity

0.15

LT Debt / Equity

0.15

EPS (TTM)

-3.49

EPS next Y

EPS next Q

EPS this Y

-17.33%

EPS next Y

EPS next 5Y

EPS last 5Y

-30.4%

Revenue last 5Y

55.95%

Revenue Q/Q

-56.69%

EPS Q/Q

-13.86%

SMA20

104.6%

SMA50

131.17%

SMA100

-38.62%

Inst Own

61.54%

Inst Trans

-1.09%

ROA

-178%

ROE

-152%

ROC

-2.15%

Gross Margin

10%

Oper. Margin

-1212%

Profit Margin

-1291%

Payout

Shs Outstand

35.07M

Shs Float

24.21M

Target Price

52W Range

0.68-18.84

52W High

52W Low

RSI

66.96

Rel Volume

0.31

Avg Volume

7.43M

Volume

2.29M

Perf Week

143.31%

Perf Month

94.17%

Perf Quarter

-72.83%

Perf Half Y

-71.87%

Beta

1.86885

Volatility

0.08%, 0.48%

Prev Close

1.52%

Price

Change

2.04%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	0.77	0.25	1	0.42	0.59
Net income per share	-14.98	-2.6	-3.35	-3.5	-2.91
Operating cash flow per share	-15.12	-2.48	-2.75	-3.84	-2.08
Free cash flow per share	-15.13	-2.63	-2.77	-3.84	-2.08
Cash per share	33.74	7.21	4.52	5.67	4.74
Book value per share	32.7	7.22	4.11	5.9	2.86
Tangible book value per share	32.84	7.24	4.11	5.9	2.86
Share holders equity per share	32.7	7.22	4.11	5.9	2.86
Interest debt per share	0	0	0	0	0.3
Market cap	32.08M	152.34M	175.79M	405.41M	342.63M
Enterprise value	-55.21M	118.26M	146.06M	320.2M	237.38M
P/E ratio	-0.83	-3.66	-2.89	-5.18	-3.82
Price to sales ratio	16.21	38.41	9.69	43.45	18.77
POCF ratio	-0.82	-3.84	-3.51	-4.72	-5.32
PFCF ratio	-0.82	-3.62	-3.49	-4.71	-5.33
P/B Ratio	0.38	1.32	2.36	3.07	3.88
PTB ratio	0.38	1.32	2.36	3.07	3.88
EV to sales	-27.9	29.82	8.05	34.32	13
Enterprise value over EBITDA	1.44	-2.87	-2.43	-4.13	-2.72
EV to operating cash flow	1.41	-2.98	-2.92	-3.73	-3.69
EV to free cash flow	1.41	-2.81	-2.9	-3.72	-3.69
Earnings yield	-1.21	-0.27	-0.35	-0.19	-0.26
Free cash flow yield	-1.22	-0.28	-0.29	-0.21	-0.19
Debt to equity	0	0	0	0	0.07
Debt to assets	0.09	0.1	0.3	0.14	0.48
Net debt to EBITDA	2.27	0.83	0.49	1.1	1.21
Current ratio	11.29	10.08	3.58	9.7	8.46
Interest coverage	0	0	0	0	-45.35
Income quality	1.01	0.95	0.82	1.1	0.72
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	5.48	3.25	0.86	2.3	2.28
Research and developement to revenue	16.61	8.54	3.62	7.18	3.53
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.06	0.01	0	0
Capex to revenue	-0.01	-0.61	-0.02	-0.02	0
Capex to depreciation	-0.07	-5.96	-0.42	-0.21	0.06
Stock based compensation to revenue	0.72	0.69	0.21	0.52	0.52
Graham number	104.98	20.56	17.61	21.54	13.67
ROIC	-0.49	-0.37	-0.8	-0.57	-0.58
Return on tangible assets	-0.41	-0.32	-0.57	-0.51	-0.52
Graham Net	31.3	6.45	3.13	4.92	2.11
Working capital	83.9M	111.9M	68.75M	124.8M	139.2M
Tangible asset value	0	0	0	0	0
Net current asset value	83.54M	111.07M	63.89M	117.73M	75.09M
Invested capital	0	0	0	0	0.08
Average receivables	4.56M	3.74M	7.36M	6.18M	4.23M
Average payables	2.31M	2.38M	2.65M	1.16M	1.13M
Average inventory	0	0	0	0	0
Days sales outstanding	542.8	119.46	171.89	241.61	45.59
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.67	3.06	2.12	1.51	8.01
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.46	-0.36	-0.82	-0.59	-1.02
Capex per share	-0.01	-0.15	-0.02	-0.01	0

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric	2021-06-30	2021-09-30	2021-12-31	2022-03-31	2022-06-30
Revenue per share	0.17	0.1	0.09	0.06	0.03
Net income per share	-0.63	-0.7	-0.91	-1.01	-0.87
Operating cash flow per share	-0.56	-0.15	-0.85	-0.87	-0.7
Free cash flow per share	-0.56	-0.15	-0.85	-0.87	-0.7
Cash per share	3.34	3.84	4.56	3.74	1.38
Book value per share	3.04	3.48	2.75	1.92	1.09
Tangible book value per share	3.04	3.48	2.75	1.92	1.09
Share holders equity per share	3.04	3.48	2.75	1.92	1.09
Interest debt per share	0.25	0.23	0.29	0.29	0.22
Market cap	414.27M	591.56M	514.44M	283.68M	24.44M
Enterprise value	350.14M	485.93M	409.19M	218.66M	-13.96M
P/E ratio	-5.58	-6.57	-4.4	-2.16	-0.21
Price to sales ratio	80.47	193.07	187.48	137.11	27.27
POCF ratio	-25.01	-119.46	-18.81	-10.05	-1.06
PFCF ratio	-25.01	-119.46	-18.84	-10.05	-1.06
P/B Ratio	4.59	5.29	5.83	4.54	0.68
PTB ratio	4.59	5.29	5.83	4.54	0.68
EV to sales	68.02	158.59	149.12	105.69	-15.58
Enterprise value over EBITDA	-19	-21.72	-15.09	-7.25	0.49
EV to operating cash flow	-21.14	-98.13	-14.96	-7.75	0.61
EV to free cash flow	-21.14	-98.13	-14.98	-7.75	0.61
Earnings yield	-0.04	-0.04	-0.06	-0.12	-1.17
Free cash flow yield	-0.04	-0.01	-0.05	-0.1	-0.94
Debt to equity	0.07	0.06	0.07	0.09	0.15
Debt to assets	0.25	0.23	0.48	0.57	0.44
Net debt to EBITDA	3.48	4.72	3.88	2.16	1.36
Current ratio	8.29	7.64	8.46	1.92	3.65
Interest coverage	0	0	-14.18	-12.14	-222.91
Income quality	0.89	0.22	0.94	0.86	0.8
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.79	3.64	4.75	7.4	8.99
Research and developement to revenue	2.81	4.71	6.28	8.2	9.12
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	-0.01
Capex to revenue	0	0	0.01	0	0.14
Capex to depreciation	0	0	0.2	0	0.44
Stock based compensation to revenue	0.42	0.76	1.07	1.55	1.47
Graham number	6.54	7.41	7.5	6.59	4.62
ROIC	-0.17	-0.18	-0.18	-0.39	-0.53
Return on tangible assets	-0.16	-0.16	-0.17	-0.23	-0.45
Graham Net	2.41	2.88	2.03	1.23	0.57
Working capital	93.49M	114.51M	139.2M	63.51M	37.73M
Tangible asset value	0	0	0	0	0
Net current asset value	76.97M	98.97M	75.09M	49.35M	24.25M
Invested capital	0.08	0.06	0.08	0.11	0.19
Average receivables	2.09M	2.29M	2.14M	1.99M	1.78M
Average payables	3.21M	3.97M	2.94M	4.78M	3.25M
Average inventory	0	0	0	0	0
Days sales outstanding	38.41	75.9	74.78	86.61	158.5
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	2.34	1.19	1.2	1.04	0.57
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.21	-0.2	-0.33	-0.53	-0.8
Capex per share	0	0	0	0	0

Frequently Asked Questions

What is Spero Therapeutics, Inc. stock symbol ?

Spero Therapeutics, Inc. is a US stock , located in Cambridge of Massachusetts and trading under the symbol SPRO

What is Spero Therapeutics, Inc. stock quote today ?

Spero Therapeutics, Inc. stock price is $2 today.

Is Spero Therapeutics, Inc. stock public?

Yes, Spero Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 7.43M
Market Capitalization 70.14M
Employee 41
CEO Dr. Ankit Mahadevia
Headquarters Cambridge,MASSACHUSETTS,US
IPO Date 2017-11-02
Website https://sperotherapeutics.com

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.